Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00039104 · ClinicalTrials.gov registry record · Phase 2

Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer

A Phase 2 study, sponsored by National Cancer Institute (NCI).

Completed
Registry status
Phase 2
Development phase
50
Enrollment target

NCT00039104: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).

NCT00039104 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 50 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add start date to calendar (.ics) →

The verdict

NCT00039104, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
Phase 2
Development phase
50 participants
Enrollment target

Study Summary

Phase II trial to study the effectiveness of combining zoledronate with BMS-275291 in treating patients who have prostate cancer that has not responded to previous hormone therapy. Zoledronate may prevent bone loss and stop the growth of tumor cells in bone. BMS-275291 may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth. Combining zoledronate with BMS-275291 may kill more tumor cells.

Interventions

  • OTHER laboratory biomarker analysis
  • DRUG zoledronic acid
  • DRUG rebimastat

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2002-04
Phase Phase 2
National Cancer Institute (NCI)

3,257 total trials

What the finished NCT00039104 record still lists

NCT00039104 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower).

The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.

NCT00039104 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00039104 about?

NCT00039104 is a clinical study titled "Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer". Phase II trial to study the effectiveness of combining zoledronate with BMS-275291 in treating patients who have prostate cancer that has not responded to previous hormone therapy. Zoledronate may prevent bone loss and stop the growth of tumor cells in bone. BMS-275291 may stop the growth of tumor c...

What is the current status of trial NCT00039104?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2002-04.

What interventions are being tested in trial NCT00039104?

The interventions under investigation include: laboratory biomarker analysis (OTHER), zoledronic acid (DRUG), rebimastat (DRUG).

Who is sponsoring clinical trial NCT00039104?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00039104's enrollment target sits among peer trials

50 1195th of 2000 higher than 740 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00039104, the US trial registry maintained by the National Library of Medicine. NCT00039104 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.